Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

p53-VP16 chimera knock-in mouse


Stanford Reference:

02-299


Abstract


Researchers in Dr. Laura Attardi’s lab have created a knock-in mouse strain which generates a form of p53 that is not subject to degradation by the proteasome. p53 is a tumor suppressor protein that senses and responds to cellular stress and is crucial for genomic stability and thus is involved in preventing cancer. In this mouse the wild-type p53 locus is replaced with a p53-VP16 fusion; such that the p53 transactivation domain is replaced with that of the VP16 transactivator protein. The p53-VP16 is silenced through an upstream floxed transcriptional stop element until Cre recombinase is expressed and the transcriptional stop element is excised. Furthermore, the Mdm-2 ubiquitin ligase binding domain has been removed thereby increasing the stability of p53. This mouse will serve as a useful model for investigating and developing p53-based cancer therapeutics.

Stage of Research
The inventors demonstrated, through analysis of mouse embryo fibroblasts derived from these mice, that upon activation of the p53-VP16 gene there is very potent growth suppression. In addition, they have shown that this fusion protein is like wild-type p53 in its ability to activate p53 target genes.


Applications


  • Basic and pre-clinical research tool for:
    • Development of cancer therapeutics.
      • Including potential for development of the fusion protein as a therapeutic for tumors lacking p53.
    • Study of p53 activities and function.

Advantages


  • Mice can show proof-of-principle efficacy in tumor suppression/regression in vivo.
  • The p53-VP16 fusion protein, as compared to wild-type p53,:
    • Has the same growth suppression and target gene activation activities.
    • Is more stable.
    • Is more potent.
    • Has the potential to be a more effective cancer therapeutic.

Publications



Related Web Links



Innovators & Portfolio



Date Released

 10/31/2012
 

Licensing Contact


Brenda Martino, Biological Materials Specialist
(650) 725-9119 (Direct)
Login to Request Information

[-] Map/Timeline

92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
97-168 Recombinase-Mediated Site Specific Integration ("Wildtype" recombinases)
97-236 Alpha 2a Adrenergic Receptor Gene Disruption Mouse (A2aARGDM)

more technologies »

Related Keywords


p53   research: cancer   gene therapy   mouse model   mouse   therapeutic: gene therapy   therapeutic: anticancer   genomics: transgenic animals   animal model   Cancer Gene Therapy   research tool: mouse model   
 

   

  

Also of Interest...
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
97-168 Recombinase-Mediated Site Specific Integration ("Wildtype" recombinases)
97-236 Alpha 2a Adrenergic Receptor Gene Disruption Mouse (A2aARGDM)

Recently Viewed...
S02-299 p53-VP16 chimera knock-in mouse